Codiak BioSciences

92 articles with Codiak BioSciences

• ATUM Announces Leap-In Transposase® Licensing Agreement with Codiak Biosciences to Support Manufacturing of Exosome-Based Therapeutics

  1/24/2023

  ATUM, a global specialist and industry leader in bioengineering solutions, announced the signing of a full licensing agreement for the Leap-In Transposase® technology with Codiak BioSciences, a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics, a new class of medicines.

• Codiak BioSciences to Participate 5th Annual Evercore ISI HealthCONx Conference

  11/28/2022

  Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that management will be participating in the 5th Annual Evercore ISI HealthCONx Conference, a virtual conference.

• Codiak Presents Preclinical Data on exoASO™-STAT6 and exoASO™-C/EBPβ Programs at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

  11/10/2022

  Codiak BioSciences, Inc. today announced new preclinical data from its exoASO™-STAT6 and exoASO™-C/EBPβ programs.

• Codiak BioSciences Reports Third Quarter 2022 Financial Results and Operational Progress

  11/3/2022

  Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, reported third quarter 2022 financial results and recent operational progress.

• Codiak Presents Preclinical Data Demonstrating its Pan Beta-Coronavirus Vaccine Elicits Broad Protective Immunity Against Known Variants of SARS-CoV-2 and Related Sarbecoviruses

  10/12/2022

  Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based candidates as a new class of medicines, today announced additional preclinical data from its pan beta-coronavirus vaccine program, which aims to protect against all SARS-CoV-2 variants of concern and potential future strains belonging to the beta-coronavirus family.

• Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity of Two Engineered Exosome Intravenous Candidates Targeting Macrophages

  10/5/2022

  Codiak BioSciences, Inc. announced that two posters featuring preclinical data from its engEx® Platform programs will be presented during the 37th Annual Meeting of the Society for Immunotherapy of Cancer, which is being held in Boston from November 8-12, 2022.

• Codiak Announces Pricing of $20 Million Public Offering of Common Stock and Warrants

  9/13/2022

  Codiak BioSciences, Inc. announced the pricing of its underwritten public offering of 13,333,333 shares of its common stock and accompanying warrants to purchase 13,333,333 shares of common stock, at a combined public offering price of $1.50 per share, together with accompanying warrants, for gross proceeds of approximately $20 million, before deducting underwriting discounts and commissions and offering expenses.

• Codiak Announces Proposed Public Offering of Common Stock and Warrants - September 12, 2022

  9/12/2022

  Codiak BioSciences, Inc. announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and accompanying warrants to purchase shares of common stock in an underwritten public offering.

• Codiak BioSciences Announces Program Reprioritization and Corporate Restructuring

  8/30/2022

  Codiak BioSciences, Inc. announced a reprioritization of its clinical and research initiatives, an acceleration of discussions related to potential strategic corporate and program-based partnerships, and a restructuring of operations to support a streamlined set of priorities.

• Codiak BioSciences Reports Second Quarter 2022 Financial Results and Operational Progress

  8/4/2022

  Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, reported second quarter 2022 financial results and recent operational progress.

• Codiak BioSciences to Participate in Upcoming BTIG and Wedbush PacGrow Investor Conferences

  8/3/2022

  Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that management will be participating in two upcoming investor conferences.

• Codiak BioSciences to Participate at William Blair Biotech Focus Conference 2022

  7/11/2022

  Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that management will be attending the William Blair Biotech Focus Conference 2022 in New York City.

• 

  The COVID-19 Pandemic: It Ain't Over 'Til It's Over

  7/5/2022

  Even though the COVID-19 pandemic appears to be under control, it's clear that it's not over, with the rise of more subvariants. Read on for more details.

• CEPI and Codiak BioSciences partner to develop broadly protective Betacoronavirus vaccine

  7/5/2022

  CEPI, the Coalition for Epidemic Preparedness Innovations, and Codiak BioSciences announced the latest funding award under CEPI’s US $200m programme to advance the development of vaccines that provide broad protection against SARS-CoV-2 and other Betacoronaviruses.

• Codiak Provides Platform-Validating Clinical Update and Data from Phase 1 Trials of exoSTING™ and exoIL-12™

  6/30/2022

  Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, announced platform-validating clinical data from Phase 1 trials of exoSTINGTM and exoIL-12™ and plans to advance both candidates into Phase 2 trials.

• Codiak Initiates Patient Dosing in Phase 1 Clinical Trial of exoASO™-STAT6 in Patients with Advanced Hepatocellular Carcinoma, Liver Metastases from Primary Gastric Cancer and Colorectal Cancer

  6/29/2022

  Codiak BioSciences, Inc. today announced the initiation of patient dosing in its Phase 1 clinical trial of exoASO-STAT6.

• Codiak Presents New Preclinical Data at ASGCT 2022 on Exosome-Based Strategy to Enhance AAV Gene Therapy

  5/17/2022

  Codiak BioSciences, Inc. announced new preclinical data on the Company’s engEx-AAV™ discovery program, a novel strategy that aims to leverage exosomes to improve adeno-associated virus vector gene therapy.

• 

  Novo Nordisk, Flagship Enter Deal For Cardiometabolic, Rare Disorder Treatments

  5/11/2022

  Flagship Pioneering has partnered with Novo Nordisk to build a portfolio of potential treatments for cardiometabolic and rare diseases.
• 

  BioSpace Movers & Shakers, May 6

  5/6/2022

  Biopharma and life sciences companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.

• Codiak BioSciences Reports First Quarter 2022 Financial Results and Operational Progress

  5/5/2022

  Codiak BioSciences, Inc. reported first quarter 2022 financial results and operational progress.